5th World Congress on Hepatitis & Liver Diseases

London, UK
August 10-12, 2017
hepatitis@gastroconferences.com
Invitation

Dear Attendees,

We are glad to announce the 5th World Congress on Hepatitis & Liver Diseases to be held in London, UK from August 10-12, 2017 organized by Conference Series Ltd in collaboration with generous support and cooperation from enthusiastic academicians and editorial Board Members.

This conference is a unique international platform that’s a confluence of all stakeholders of the ecosystem – Industry, Academia, Researchers, Innovators, Regulators – coming together to present and discuss current topics in Hepatitis, Herbal Hepatotoxicity, Non-viral hepatitis, Hepatitis vaccination, Hepatocellular carcinoma, Liver diseases, Liver diseases diagnosis, Pregnancy and Liver Diseases, Liver Transplantation and Surgery and HCV/HIV coinfection.

As the premier event, we have developed a program with your interests in mind. We have not only increased the number of opportunities for you to network with colleagues from across the world but also introduced more focused sessions that will feature cutting edge presentations, special panel discussions, and livelier interaction with industry leaders and experts.

Life is full of give and take. Make it count in your professional life. Attend the Hepatitis Conference to network with your peers, exchange expertise and experiences and arm yourself with the latest information to take your department to the next level.

We look forward to personally welcoming you to London this August.

Sincerely,

Hepatitis 2017
Organizing Committee

Conference Website: http://hepatitis.conferenceseries.com/
Hepatitis is an inflammatory condition of the liver caused by the hepatitis virus. The most observed types of this disease are hepatitis A, hepatitis B and hepatitis C. Globally, 350 million people are chronically infected with any one form of hepatitis and around 500,000 people die every year according to World Health Organization.

Hepatitis A is a simpler form of which does not lead to chronic infections. Patients suffering from hepatitis A recover within two months as this form is less complicated and can be prevented with vaccination.

Although hepatitis B can be prevented by vaccination, once infected, a person can develop lifelong chronic infection resulting into severe liver damage. More than 2 billion people of the global population are infected with hepatitis B. Hepatitis B patients are vulnerable to further complications related to the liver, such as: hepatocellular carcinoma (liver cancer), liver failure, and liver cirrhosis.

Hepatitis C is most dangerous of among all the types of hepatitis as 80% of the hepatitis C infected patients get chronically infected. Around 150 million people are infected with hepatitis C worldwide and 350,000 people die every year. It has a cure rate of less than 80%, which drops below 60% in some regions of the world. The low cure rate is supplemented in most regions by a lack of an effective vaccine against hepatitis C. Recent estimates find that about 215,000 people in the UK are chronically infected with hepatitis C.

The global demand for Hepatitis C drug Market is expected to reach 27.63 billion USD in 2021 at a CAGR of 17% between 2016 and 2021, which was 11.81 billion USD in 2015. Key applications of hepatitis C drug market are hospitals, private labs, public health labs, blood banks and physician offices. Hepatitis C drug market can be driven by the elements like prevalence of the infection, new productive treatments, rising government subsidizing and relatively lesser time of treatment. Hepatitis C market can be influenced by treatment costs, lack of awareness and information about HCV disease.

In the United States, 20 percent to 30 percent of people living with HIV are coinfected with HCV. Hepatitis C is common among people living with HIV. This means that about 225,000 to 330,000 people in the United States are living with both viruses. The majority of people living with hepatitis C do not know they have it. The most common route of transmission in the UK is using non-sterile needles and other equipment for injecting drugs. 90 percent of people who got HIV from injecting drugs are also infected with HCV. This is because both viruses can be spread easily through blood and blood products.

HBV therapeutics market grow from $2.4 billion in 2014 to $3.0 billion in 2024 at a compound annual growth rate (CAGR) of 2.4%.

Siemens AG, MedMira Inc., Inovio Pharmaceuticals, Inc. and Abbott Laboratories are lead players involved in the development of hepatitis diagnostics.

Gilead Sciences launched couple of drugs Harvoni ((ledipasvir/sofosbuvir) and Sovaldi (sofosbuvir) in the market for Hepatitis C which captured maximum market share and has cure rate of more than 95%. In the coming years, ongoing research on hepatitis C drug development in pharmaceutical industry is expected to increase the market growth. Due to prevalence of the disease, interest for Hepatitis C medication is expanding in Africa, Middle East, Asia Pacific and Latin America.

Liver Associations

Conference Website: [http://hepatitis.conferenceseries.com/](http://hepatitis.conferenceseries.com/)
London, UK

• European Association for the Study of the Liver (EASL)
• EuroLiver Foundation
• British Association for the Study of the Liver (BASL)
• British Liver Trust - National charity for adult liver disease
• American Association for the Study of Liver Diseases (AASLD)
• American Hepato-Pancreato-Biliary Association (AHPBA)
• American Liver Foundation (ALF)
• Texas Society for Gastroenterology and Endoscopy
• International Hepato Pancreato Biliary Association (IHPBA)
• Canadian Association for the Study of the Liver (CASL) - Canada (CA)
• Canadian Liver Foundation (CLF) - Canada (CA)
• Latin American Association for the Study of the Liver (ALEH)
• International Association for the Study of the Liver (IASL)
• Childhood Liver Tumour Study Group (SIOPEL)
• Liver Kids Australia
• Children’s Liver Disease Foundation (CLDF)
• Hepatitis B Foundation
• Hepatitis Foundation International
• Asian Pacific Association for the Study of the Liver (APASL)
• Hong Kong Liver Foundation - Hong Kong (HK), China
• Immunization Action Coalition

• International Liver Transplantation Society (ILTS)
• Swiss Association for the Study of the Liver (SASL) - Switzerland (CH)

Medical Colleges in UK
• Imperial College London
• University College London
• King’s College London
• Queen Mary University of London
• St. George’s, University of London
• The University of Buckingham
• University of Oxford
• University of Cambridge
• University of Southampton
• Hull York Medical School
• Cardiff University School of Medicine
• Keele University School of Medicine
• University of Glasgow
• Warwick Medical School
• Brighton and Sussex Medical School
• Norwich Medical School
• University of Aberdeen

Conference Website: http://hepatitis.conferenceseries.com/
Drug Approvals and Launches:

In 2012, the European Commission approved the use of Viread for the treatment of chronic HBV infection. Viread is also approved for the treatment of HIV infection.


In October 2014, Gilead received FDA approval and in November 2014 Gilead received European Commission approval of Harvoni, the first once-daily single tablet regimen for the treatment of HCV genotype 1 infected patients. Patent expiration for Harvoni in USA and EU is 2030.

In December 2014, VIEKIRA PAK was approved by the FDA.

In July 2015, the FDA approved AbbVie’s Technivie for use in combination with ribavirin for the treatment of adults with genotype 4 HCV infection in the United States.

In January 2016, the FDA approved Zepatier for the treatment of adult patients with chronic HCV GT1 or GT4 infection, with or without ribavirin. Patent expiration for Intron A and Zepatier in USA is 2020 and 2031 respectively.

Novira Therapeutics is developing a lead core inhibitor candidate, NVR 3-778. NVR 3-778 is a potent inhibitor of HBV replication both in cell culture models and a humanized liver mouse model of CHB. It disrupts the HBV lifecycle by inducing the assembly of defective capsids. NVR 3-778 is currently under Phase 1 clinical trial in New Zealand.

Other Novira therapeutics drug such as “2nd Generation Core Inhibitor” and “cccDNA” inhibitor are under discovery stage of development.

FDA approved Drugs for HBV treatment:

Baraclude (entecavir)
Epivir HBV (lamivudine)
Viread (tenofovir disoproxil fumarate)
Hepsera (adefovir dipivoxil)
Pegasys (pegylated interferon)
Intron A (interferon alpha-2b)
Tyzeka (telbivudine)
FDA approved Drugs for HCV treatment:

- CoPegus (ribavirin)
- Daklinza (daclatasvir)
- Epclusa (sofosbuvir, velpatasvir)
- Harvoni (ledipasvir/sofosbuvir)
- Incivek (telaprevir)
- Infergen (interferon alfacon-1)
- Olysio (simeprevir)
- Pegintron (pegylated interferon alpha-2b)
- Rebetol (ribavirin)
- Roferon (interferon alpha-2a)
- Sovaldi (sofosbuvir)
- Technivie (ombitasvir, paritaprevir and ritonavir)
- Victrelis (boceprevir)
- Viekira Pak (ombitasvir, paritaprevir and ritonavir tablets co-packaged with dasabuvir tablets)
- Zepatier (elbasvir, grazoprevir)

Companies manufacturing Liver equipment’s

- Echosens
- KMC Systems
- Argon Medical devices Inc
- Humedics

FDA approved drugs in 2016 for Hepatology

- Defitelio
- Ocaliva

<table>
<thead>
<tr>
<th>Name</th>
<th>Manufacturer</th>
<th>2013</th>
<th>2014</th>
<th>2015</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baraclude</td>
<td>Bristol-Myers Squibb</td>
<td>$1.52 Millions</td>
<td>$14.4 Millions</td>
<td>$1.31 Millions</td>
</tr>
<tr>
<td>Viread</td>
<td>Gilead</td>
<td>$959 Millions</td>
<td>$1.05 Millions</td>
<td>$1.10 Millions</td>
</tr>
<tr>
<td>Harvoni</td>
<td>Gilead</td>
<td>-</td>
<td>$2.12 Millions</td>
<td>$13.86 Millions</td>
</tr>
<tr>
<td>Incivek</td>
<td>Vertex Pharmaceuticals</td>
<td>$466.36 Millions</td>
<td>$24.07 Millions</td>
<td>$17.98 Million</td>
</tr>
<tr>
<td>Olysio</td>
<td>Janssen Therapeutics</td>
<td>$23 Millions</td>
<td>$2.30 Millions</td>
<td>$621 Millions</td>
</tr>
<tr>
<td>Pegintron</td>
<td>Merck</td>
<td>$496 Millions</td>
<td>$381 Millions</td>
<td>$182 Millions</td>
</tr>
<tr>
<td>Sovaldi</td>
<td>Gilead</td>
<td>$139 Millions</td>
<td>$10.28 Millions</td>
<td>$5.27 Millions</td>
</tr>
<tr>
<td>Victrelis</td>
<td>Merck</td>
<td>$428 Millions</td>
<td>$153 Million</td>
<td>$18 Million</td>
</tr>
<tr>
<td>Viekira Pak</td>
<td>AbbVie Inc</td>
<td>-</td>
<td>$48 Millions</td>
<td>$1.63 Million</td>
</tr>
</tbody>
</table>

List of Manufacturing Companies:

- Bristol-Myers Squibb
- GlaxoSmithKline
- Gilead Sciences
- Schering
- Roche
- Novartis
- Vertex Pharmaceuticals
- Three Rivers Pharma
- Janssen Pharmaceuticals
- AbbVie Inc.

Hepatitis 2017

Conference Website: http://hepatitis.conferenceseries.com/
Drugs in Clinical Development:

Tenofovir Alafenamide Fumarate (Gilead): TAF is a nucleotide reverse transcriptase inhibitor currently under Phase III stage of development for the treatment of Chronic HBV infection.

GS-9620 (Gilead): GS-9620 is a TLR-7 agonist indicated for Chronic HBV infection is under Phase II stage of development.

GS-4997 (Gilead): GS-4997 is an ASK-1 inhibitor indicated for NASH and alcoholic hepatitis is currently under Phase II stage of development.

GS-9674 (Gilead): GS-9674 is a FXR agonist indicated for NASH, Primary Sclerosing Cholangitis and Primary biliary cirrhosis is currently under Phase II stage of development.

GS-0976 (Gilead): GS-0976 is an ACC Inhibitor indicated for NASH is currently under Phase II stage of development.

3228836 (Glaxosmithkline): 3228836 is a HBV antisense oligonucleotide indicated for hepatitis B is currently under Phase I stage of clinical development.

3389404 (Glaxosmithkline): 3389404 is a HBV LICA antisense oligonucleotide indicated for hepatitis B is currently under Phase I stage of clinical development.

2878175 (Glaxosmithkline): 2878175 is a non-structural protein 5B (NS5B) polymerase inhibitor indicated for hepatitis C is currently under Phase I stage of clinical development.

ARO-HBV (Arrowhead): ARO-HBV is being developed for patients with chronic hepatitis B infection. It is currently under preclinical stage of development.

ARO-AAT (Arrowhead): ARO-AAT is being developed to treat the liver disease associated with alpha-1 antitrypsin deficiency. It is currently under preclinical stage of development.

Myrcludex-B (MYR GmbH): Myrcludex B, a first-in-class drug for treatment of chronic hepatitis B (HBV) and chronic hepatitis delta (HDV) infection completed Phase 2a clinical trial in chronic hepatitis B and a pilot trial in HDV infection is ongoing.
About Us

Our International Open Access Journals
- 700+ Leading-edge Peer Reviewed Open Access Journals
- 21 Day Rapid Review Process
- 50000+ Editorial Board Team, 35000+ Reviewers team
- 30 Million Readers and High Visibility
- 1000+ Scientific Associations Collaborations
- 100000+ Likes
- Publication immediately after acceptance
- Quality and Quick editorial, review processing

Salient Features
- Easy to Submit and Review Systems
- High Quality and Fast Publishing Guaranteed
- Unbiased, quality-oriented, and transparent reviews
- Truly impartial recognition of the best papers
- Feedback on the impact of every article
- Enhanced feature: Audio version of published paper
- Digital articles to share and explore
- Sharing option: Social networking enabled
- Authors, reviewers and editors are provided with scientific credits
- User friendly/feasible website articles translations across more than 50 world languages

Our International Scientific Conferences
- More than 3000 Conferences happening across the globe
- Conferences organized in Medical, Pharma, Engineering, Science, Technology and Business.
- CME/CPD Accredited Conferences fostering professional and Personal development
- Continuum of education through organized scientific program
- Renowned speakers and scientists representing from 40 countries
- Highly Interactive sessions and Panel Discussions
- B2B Meetings offers perfect platform for Global Networking

Salient Features
- Robust on-line publicity for all the speakers and organizing committee members
- Career Guidance Workshops for students and early career researchers
- Accepted Abstracts will be published in various indexed journals
- Accepted abstracts will be labeled with a Digital Object Identification Number (DOI) provided by Cross Ref
- Creation of speakers and abstracts pages in Google
- Opportunity to publish full Manu Scripts in our Open Access Journals

Special Issues: All accepted abstracts will be published irrespective Conference Series LLC Journals
Each abstract will be provided with digital Object Identifier by CrossRef
**About Conference**

**Hepatitis 2017** Conference website is attracting 25000+ Hepatologists, Gastroenterologists, Virologists, online visitors ranging from Researchers, Academicians and Business professionals, who are working in this field. This unique opportunity that we extend to our speakers and attendees is not being offered by any other conference organizers. Through this the abstracts and research profiles of our speakers and organizing committee members getting global visibility which is an additional feature that you would be receiving in addition to networking opportunities before, during and after the conference.

**How Conference Series Conferences differs from others?**

- **3000+ Conferences** across the globe in 30+ countries all through the year
- Over **25 Million+ Visitors** and **20000+ Unique Visitors** per conference
- Participation by Stalwarts from various international societies
- Internationally renowned speakers and scientists representation
- Career guidance for early career researchers and students
- Interesting scientific deliberations and discussions
- Perfect platform for Global Networking

**Hepatitis 2017 salient features**

- Meet Academia and Industry visionaries to get inspired
- Expand your knowledge and find solutions to problems
- Knowledge, Benchmarking and Networking offered at one place
- Forge connections and for global networking
- Highly Organized and Structured Scientific programs
- Poster presentations and world class exhibitions
- Meet with new vendors and suppliers

**Conference Website:** [http://hepatitis.conferenceseries.com/](http://hepatitis.conferenceseries.com/)
About Conference

Purpose

5th World Congress on Hepatitis & Liver Diseases is an arena for interdisciplinary exchange among professionals in the fields of Hepatology, Gastroenterology and Virology.

Goals

• The conference program emphasizes evidence-based practice, educational innovation, practical application, and peer to peer networking and collaboration. The goals of the conference is to provide a transformative professional development experience through

• Bringing together the world’s scientific experts to catalyze and advance scientific knowledge about Hepatitis and Liver diseases present the most recent research findings, promote and enhance scientific collaborations around the world

Objectives

After participating in this meeting, attendees should be able to

• Discuss emerging issues in the field of Liver diseases

• Discuss and apply recent research findings related to Hepatitis

Conference Website: http://hepatitis.conferenceseries.com/
About Conference

Who should attend
5th World Congress on Hepatitis & Liver Diseases is exclusively designed for Hepatologists, Gastroenterologists, Virologists, Toxicologists, Microbiologists, Pathologists, Oncologists, Researchers, Students, Business delegates and Young researchers across the globe.

About hosting organization
Conference Series is the world’s leading specialist in organizing Academic, Scientific and Business conferences, meetings, symposiums and exhibitions in different verticals and horizontals like Medical, Pharma, Engineering, Science, Technology and Business to promote scientific research. Every year we host more than 3000+ global events inclusive of 1000+ Conferences 1000+ Symposiums 1000+ Workshops in USA, Europe, Middle East and Asia with the generous support and cooperation from our 30000+ Editorial Board Members, 1000+ Scientific Societies. All the conference proceedings are published in the special issues of our 700+ Open Access International Journals with the DOI provided by CrossRef.

Major sessions
- Hepatitis B
- Hepatitis C
- Herbal medicines for Liver diseases
- Non-Viral Hepatitis
- Hepatitis Vaccination
- Hepatocellular Carcinoma
- Liver Diseases Diagnosis

- Liver Diseases
- Gastroenterology
- Pregnancy and Liver Diseases
- Liver Transplantation and Surgery
- HCV/HIV Coinfection
- Entrepreneurs Investment Meet

Conference Website: http://hepatitis.conferenceseries.com/
About Conference

Supporting Journals

• Journal of Liver
• Journal of Liver Disease and Transplantation
• Journal of Gastrointestinal & Digestive System

Media partners/Sponsors

Hepatitis 2017

Conference Website: http://hepatitis.conferenceseries.com/
London is the capital and most populous city of England and the United Kingdom. Standing on the River Thames in the southeast of Great Britain. It was founded by the Romans, who named it Londinium. It is one of the world’s leading financial centres and has the fifth-or sixth-largest metropolitan area GDP in the world depending on measurement. London is a world cultural capital. It is the world’s most-visited city as measured by international arrivals and has the world’s largest city airport system measured by passenger traffic. It is the world’s leading investment destination, hosting more international retailers and ultra high-net-worth individuals than any other city. London’s 43 universities form the largest concentration of higher education institutes in Europe, and according to 2014 report it is placed first in the world university rankings. According to the report London also ranks first in the world in software, multimedia development and design, and shares first position in technology readiness.

London has a diverse range of peoples and cultures, and more than 300 languages are spoken. The Office for National Statistics estimated its mid-2014 population to be 8,538,689, the largest of any municipality in the European Union, and accounting for 12.5 percent of the UK population. It is a leading global city, with strengths in the arts, commerce, education, entertainment, fashion, finance, healthcare, media, professional services, research and development, tourism, and transport all contributing to its prominence. Other famous landmarks include Buckingham Palace, the London Eye, Piccadilly Circus, St Paul’s Cathedral, Tower Bridge, Trafalgar Square, and The Shard. It is the home to numerous museums, galleries, libraries, sporting events and other cultural institutions, including the British Museum, National, Tate Modern, British Library and 40 West End theatres.
Venue & Accommodation

London, UK

Contact Us

Program Director | Hepatitis 2017 Conference Series
Kemp House, 152 City Road, London EC1V 2NX
W: hepatitis.conferenceseries.com
E: hepatitis@gastroconferences.com

Venue Map

Conference Website: http://hepatitis.conferenceseries.com/
Registrations

**ACADEMIC**

Only Registration: **USD 799**  
Package A (Registration + 3 nights’ Accommodation): **USD 1294**  
Package B (Registration + 4 nights’ Accommodation): **USD 1459**

**BUSINESS**

Only Registration: **USD 899**  
Package A (Registration + 3 nights’ Accommodation): **USD 1394**  
Package B (Registration + 4 nights’ Accommodation): **USD 1559**

**STUDENT**

Student Oral: **USD 349**  
Student Poster: **USD 349**  
Student Delegate: **USD 249**  
E-poster: **USD 99**

**Important Dates**

Abstract submission opens: **November 10, 2016**  
Registration opens: **November 20, 2016**  
Early bird registration: **April 30, 2017**  
On spot registration: **August 10, 2017**

To register online, please visit:  
http://hepatitis.conferenceseries.com/registration.php